<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04585308</url>
  </required_header>
  <id_info>
    <org_study_id>CLP-05-001</org_study_id>
    <nct_id>NCT04585308</nct_id>
  </id_info>
  <brief_title>transShield Embolic Protection System Feasibility Study</brief_title>
  <official_title>Prospective, Multi-center, Single-Arm Feasibility Study of the transShield Embolic Protection System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TransAortic Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TransAortic Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and performance of the transShield&#xD;
      Embolic Protection System (EPS) used for embolic protection during Transcatheter Aortic Valve&#xD;
      Replacement (TAVR).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, single arm feasibility study to assess the safety and&#xD;
      performance of the transShield EPS. Patients with severe native aortic valve stenosis&#xD;
      scheduled for TAVR will be screened for study eligibility. Subjects who meet the commercially&#xD;
      approved indications for TAVR and comply with the study inclusion/exclusion criteria are&#xD;
      eligible for enrollment. Patients will be followed for 30 days post procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Incidence of 30-Day combined rate of the following events directly related to the transShield EPS as defined by VARC-2</measure>
    <time_frame>30 day combined rate post-procedure</time_frame>
    <description>Major Adverse Cardiac and Cerebrovascular Events (MACCE)&#xD;
All cause mortality&#xD;
All cause stroke (disabling and non-disabling)&#xD;
Acute kidney injury (Stage 2 or 3)&#xD;
Major vascular complications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance - Technical Success defined as the transShield EPS ability to perform all the following functions without adjudicated device malfunction</measure>
    <time_frame>During the procedure</time_frame>
    <description>Ability to successfully deploy the device in the correct anatomical position, in the ascending aorta without interference with TAVR procedure/devices&#xD;
Ability to retrieve and remove the device intact, including no visual evidence of any filter damage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - Incidence of minor vascular complications directly related to the transShield EPS as defined by VARC-2.</measure>
    <time_frame>30 days post-procedure</time_frame>
    <description>As defined by VARC-2.&#xD;
Incidence of peri-procedural disabling stroke as defined by a modified Rankin Scale (mRS) score of 2 or more at 30 days and an increase in at least one mRS category from an individual's pre-stroke baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with severe native aortic valve stenosis who meet the commercially approved indications for TAVR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transShield Embolic Protection System</intervention_name>
    <description>Used for embolic protection during TAVR.</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must meet all of the following criteria to be eligible for participation in&#xD;
             the study:&#xD;
&#xD;
               -  Patient is &gt;18 years old&#xD;
&#xD;
               -  Patient is scheduled for percutaneous TAVR with up to 20French compatible&#xD;
                  commercial TAVR system&#xD;
&#xD;
               -  Patient meets indications for TAVR per the device Instructions For Use&#xD;
&#xD;
               -  The diameter of the artery at the site of the filter placement is between 28 mm&#xD;
                  and 42 mm&#xD;
&#xD;
               -  Size and condition of the femoral artery iliac arteries are appropriate for the&#xD;
                  12French transShield Expandable Introducer and 20F Embolic Protection Device&#xD;
&#xD;
               -  Patient, or authorized representative, signs a written Informed Consent form to&#xD;
                  participate in the study, prior to any study mandated procedures&#xD;
&#xD;
               -  Patient is willing and able to complete follow-up requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients must be EXCLUDED from participation in this study if any of the following&#xD;
             criteria are met:&#xD;
&#xD;
               -  Patient not undergoing TAVR via the trans-femoral route&#xD;
&#xD;
               -  Carotid artery stenosis &gt;70% in either carotid artery&#xD;
&#xD;
               -  Severe vascular tortuosity or anatomy that would preclude the safe introduction&#xD;
                  of the device&#xD;
&#xD;
               -  Aortic valve is a congenital unicuspid or congenital bicuspid valve or is&#xD;
                  non-calcified&#xD;
&#xD;
               -  Mixed aortic valve disease (aortic stenosis and aortic regurgitation with&#xD;
                  predominant aortic regurgitation &gt;3+)&#xD;
&#xD;
               -  A known contraindication or hypersensitivity to all anticoagulation regimens or&#xD;
                  an inability to undergo anticoagulation for the study procedure&#xD;
&#xD;
               -  History of bleeding diathesis or in whom anticoagulant and/or anti-platelet&#xD;
                  therapy is contraindicated, patients who will refuse transfusion, or havean&#xD;
                  active peptic ulcer or upper GI bleeding within the prior 3 months&#xD;
&#xD;
               -  Renal insufficiency, defined as a creatinine level &gt; 221μmol/L and/or end-stage&#xD;
                  renal disease requiring chronic dialysis at time of treatment&#xD;
&#xD;
               -  History of stroke or transient ischemic attack (TIA) within prior 6 months&#xD;
&#xD;
               -  Evidence of an acute myocardial infarction (MI) within prior 30 days&#xD;
&#xD;
               -  Hemodynamic or respiratory instability requiring inotropic support, mechanical&#xD;
                  ventilation, or mechanical heart assistance within prior 30 days&#xD;
&#xD;
               -  Hypertrophic cardiomyopathy with or without obstruction&#xD;
&#xD;
               -  Need for emergency surgery for any reason•Severe left ventricular (LV)&#xD;
                  dysfunction with LV ejection fraction (LVEF) &lt;20%&#xD;
&#xD;
               -  Severe pulmonary hypertension and right ventricular (RV)&#xD;
                  dysfunction•Echocardiographic evidence of intracardiac mass, thrombus or&#xD;
                  vegetation&#xD;
&#xD;
               -  Life expectancy &lt; 12 months due to non-cardiac co-morbid conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Webster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Auckland City Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Forro</last_name>
    <phone>(508) 254-1005</phone>
    <email>aforro@linceconsulting.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Mazhar</last_name>
    <phone>(415) 269-7580</phone>
    <email>smazhar@linceconsulting.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <state>Grafton</state>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandy Fish</last_name>
      <phone>00 64) 09 307 4949</phone>
      <phone_ext>24366</phone_ext>
      <email>mfish@adhb.govt.nz</email>
    </contact>
    <investigator>
      <last_name>Mark Webster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Forro</last_name>
      <phone>(508) 254-1005</phone>
      <email>aforro@linceconsulting.com</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Mazhar</last_name>
      <phone>4152697580</phone>
      <email>smazhar@linceconsulting.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sanjeevan Pasupati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

